E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 years of disease duration (from diagnosis). Patients treated with immunomodulatory drugs or treated with first-line injectable therapies (eg interferons or glatiramer acetate) may be included. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with newly diagnosed multiple sclerosis (MS) or with symptoms and signs giving rise to high suspicion of MS, either non-treated or treated with first-line injection therapies. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is • To compare clinical efficacy between rituximab administered according to a Swed-ish treatment schedule and dimethyl fumarate administered according to label
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the study are • To compare effects on magnetic resonance imaging from treatment with rituximab and dimethyl fumarate • To compare effects on cerebrospinal fluid markers for axonal damage from treat-ment with rituximab and dimethyl fumarate • To compare effects on serum levels of the axonal injury marker neurofilament light from treatment with rituximab and dimethyl fumarate • To compare the rate of disability progression during the trial • To make health economic assessments, including work capacity, and compare cost – effectiveness between Rituximab and dimethyl fumarate • To compare patient satisfaction and health related quality of life during long-term treatment of RRMS patients with Rituximab and dimethyl fumarate
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
In early multiple sclerosis, compare the two drugs rituximab and dimethyl fumarate in their ability to prevent nerve damage measured as release of the biomarker Neurofilament Light in the cerebrospinal fluid |
|
E.3 | Principal inclusion criteria |
A subject will be eligible for inclusion in this study if all of the following criteria apply:
• Diagnosis of Relapsing Remitting MS according to the 2017 revised McDonald criteria OR one demyelinating episode in conjunction with at least one asymptomatic high intensity T2 lesion with size and location compatible with MS • Untreated OR treated with first line injectables (interferon or glatiramer acetate) • Between the age of 18 and 50 years (inclusive) of age • No more than 10 years of disease duration (since MS diagnosis) • During the previous year, clinical or radiological disease activity defined as at least one of the following: o ≥ 1 relapse o ≥ 2 T2 lesions o ≥ 1 Gd+ lesions • EDSS 0 – 5,5 (inclusive) In fertile females, willing to comply with effective contraceptive methods. These include birth control pills, surgical sterilization of patient or partner or intrauterine device. Non-fertile women is defined as more than 12 months of amenorrhea |
|
E.4 | Principal exclusion criteria |
A subject will not be eligible for inclusion in this study if any of the following criteria ap-plies:
• Diagnosis of Progressive MS • Pregnant or lactating women • Patients having contraindication for or otherwise not compliant with MRI investigations • Simultaneous treatment with other immunosuppressive drugs • Documented allergy or intolerance to any of the IP:s • Severe psychiatric condition
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoints of this study is • The relative risk of experiencing a relapse during the two–year period for either compound.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
While all subjects in the trial has received treatment with either of the IMP for two years |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints are • Treatment effect evaluated via MRI - Numbers of Gd+ lesions and new/enlarging T2 lesions - Evolution of brain atrophy measured as brain parenchymal fraction (BPF) • Treatment effect evaluated via levels of Neurofilament-Light protein in the CSF - The patients will be asked to participate in this part as an optional study involving LP at four occasions. • Treatment effect evaluated via levels of Neurofilament-Light protein in the serum • Treatment effect as confirmed worsening evaluated via EDSS - Proportion of patient with confirmed progression in EDSS according to pre-specified criteria - The mean change in EDSS over the trial period • Proportion of patients with No Evidene of Disease Activity (NEDA) -3 (free of ex-acerbations, new/enlarged T2-lesions and occurrence of Gd+ lesions) as well as NEDA-4 (NEDA-3 plus no worsening of EDSS from baseline) • Proportion rescue treatments from insufficient treatment effect determined by MRI in the two treatment arms |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
While all subjects in the trial has received treatment with either of the IMP for two years |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 18 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject undergoing the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |